Cardiff Oncology (CRDF) EBIT (2011 - 2026)

Cardiff Oncology has reported EBIT for 15 years, with the latest figure at -$7.8 million in Q4 2025.

• Quarterly EBIT rose 37.74% year-over-year to -$7.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$49.0 million (down 0.64% YoY) and the FY2025 annual result came in at -$49.0 million, down 0.64% from the prior year.
• EBIT improved to -$7.8 million in Q4 2025 per CRDF's latest filing, from -$12.0 million in the prior quarter.
• Over five years, EBIT peaked at -$5.4 million in Q1 2021 and troughed at -$14.8 million in Q2 2025.
• A 5-year average of -$10.6 million and a median of -$10.9 million in 2023 frame the typical range for EBIT.
• The sharpest annual moves came in 2022 and 2025: EBIT slumped 103.49% in 2022, then jumped 37.74% in 2025.
• Over 5 years, EBIT stood at -$9.5 million in 2021, then advanced by 1.41% to -$9.4 million in 2022, then fell by 10.01% to -$10.3 million in 2023, then declined by 21.68% to -$12.6 million in 2024, then surged by 37.74% to -$7.8 million in 2025.
• According to Business Quant data, EBIT over the past three periods registered -$7.8 million, -$12.0 million, and -$14.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.